Lumida
/OFIX
⌘K
Orthofix Medical Inc

Orthofix Medical Inc

OFIX
$8.93USD↑+2.76%+0.24 today

MARKET CAP

363.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$9 – $9

52W RANGE

$9
$17

AI Summary

Stalk
TrimMedium

The asset remains in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price has been rejected at the 9/20 EMA band repeatedly, reinforcing a medium-term bearish bias. Oversold status does not grant mean-reversion permission, and short-term timing is neutral. Execution should be deferred into future rally attempts into EMA resistance rather than sold immediately. A Trim is recommended to seek a better entry point on a bounce into the EMAs.

  • ↑Q2 EPS of $0.07 beats est; revenue $210.9M (+4% YoY).
  • ↑Global Spine Fixation and Limb Reconstruction segments up double digits.
  • ↓Q2 net loss widened to $15.8M despite revenue gains.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Orthofix Medical Inc. (NASDAQ: OFIX) is a leading provider of orthopedic and regenerative medicine products, with a strong focus on spinal and orthopedic solutions. The company operates primarily within the healthcare industry, specifically targeting surgical and rehabilitation markets. Orthofix's positioning within the orthopedic market, coupled with its innovative product offerings, positions the company for continued growth, especially with the recent restoration of Medicare reimbursements for key products.

Bull says

  • ↑Q2 EPS of $0.07 beats est; revenue $210.9M (+4% YoY).
  • ↑Global Spine Fixation and Limb Reconstruction segments up double digits.
  • ↑Full-year sales guidance raised to $845–855M; EBITDA guide to $95–98M.
  • ↑Analyst consensus is 'Strong Buy' with ~27% upside potential.
  • ↑Bullish moving-average crossover and Aroon uptrend signal momentum.
  • ↑High book-to-price, strong 13F ownership, and short-interest support.

Bear says

  • ↓Q2 net loss widened to $15.8M despite revenue gains.
  • ↓Negative profitability and growth metrics signal inefficiencies.
  • ↓High leverage exposes the company to liquidity and market risks.
  • ↓Shares fell ~15% post-earnings, reflecting investor skepticism.
  • ↓Spine market disruptions and competition may constrain growth.
  • ↓Weak earnings yield and no dividend limit capital returns.

Investment themes with OFIX

Medical Devices↓ -0.50%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-07-2025bullish

Transcript signals

Bull points

  • We have solid fundamentals, exceptional employees and a best-in-class portfolio that is driving above-market performance.
  • Throughout 2024, we will keep delivering on our commitments to patients, customers and shareholders, driving the company to new heights.
  • We have solid fundamentals, exceptional employees and a best-in-class portfolio that is driving above-market performance.
Read full transcript analysis ›